This disclosure relates to a device to determine or quantify the presence of an analyte molecule, virus or cell of interest in a sample. The present disclosure also relates to a method to determine or quantify the presence of an analyte molecule, virus or cell of interest in a sample, a method of preparing the device of the disclosure, the use of the device of the disclosure for determining or quantifying the presence of an analyte molecule, virus or cell of interest in a sample and a kit of parts comprising the device of the disclosure.

The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of ZIKV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of ZIKV infection.

A method for making and a resultant paper test strip product for detecting Zika antibodies indicating the presence of Zika virus in a patient sample. The paper test strip includes a strip of filter paper; and a silk fibroin solution applied to the strip of filter paper wherein the silk fibroin solution is mixed with an enzyme solution in phosphate buffered saline buffer.

A recombinant vector for transforming a plant, a plant transformed with the recombinant vector, a plant-made classical swine fever virus antigen pmE2 protein expressed in the plant and uses thereof is provided. By using a recombinant vector having a polynucleotide encoding a GP55 protein of CSFV according to the present invention; and a polynucleotide encoding a cellulose-binding domain protein; and a plant transformed with the recombinant vector, a plant-made classical swine fever virus antigen pmE2 protein may be produced with high efficiency, and has higher safety and stability than those achieved by other production methods. Also, since the plant-derived classical swine fever virus antigen protein pmE2 has a cellulose-binding domain (CBD) protein, it may be usefully used as an effective marker to determine a virus exposure pathway and an antibody producing pathway.

It was discovered that hydrogel scaffolds can be used to induce phase separation as aqueous two-phase systems (ATPSs) pass through and/or rehydrate the scaffolds, allowing for concentration of target analyte(s) (e.g., biomolecule(s)) into a particular phase of the ATPS or into a leading front. Accordingly, in various embodiments methods and devices are provided that utilize aqueous two-phase systems and hydrogel scaffolds to improve the sensitivity of assays (e.g., of point-of-care assays) without sacrificing cost or ease of use.

The present invention relates to compositions and methods involving diagnostic tests with multiple test antigens. The present invention involves the expanded use of test antigens as cross-reactive control antigens (CCAs). The invention advantageously provides for enhanced test results analysis by simultaneously providing both test antigen and CCA signal results. These results, in turn, allow useful sample comparison and cross-reference between samples to more accurately identify and verify the fidelity of test results obtained for multiple infective agents at once. The present invention may include compositions and methods for detecting infection by Zika virus or another flavivirus, and may distinguish between infections caused by genetically similar agents.

A recombinant vector for transforming a plant, a plant transformed with the recombinant vector, a plant-made classical swine fever virus antigen pmE2 protein expressed in the plant and uses thereof is provided. By using a recombinant vector having a polynucleotide encoding a GP55 protein of CSFV according to the present invention; and a polynucleotide encoding a cellulose-binding domain protein; and a plant transformed with the recombinant vector, a plant-made classical swine fever virus antigen pmE2 protein may be produced with high efficiency, and has higher safety and stability than those achieved by other production methods. Also, since the plant-derived classical swine fever virus antigen protein pmE2 has a cellulose-binding domain (CBD) protein, it may be usefully used as an effective marker to determine a virus exposure pathway and an antibody producing pathway.

Provided herein are compositions, methods, and kits for detecting human Pegivirus 2 (HPgV-2). In certain embodiments, provided herein are HPgV-2 specific nucleic acid probes and primers, and methods for detecting HPgV-2 nucleic acid. In other embodiments, provided herein are HPgV-2 immunogenic composition compositions, methods of treating a subject with immunogenic HPgV-2 peptides, and methods of detecting HPgV-2 subject antibodies in a sample.

Systems and methods are described herein for a diluent-containing tube comprising a beveled grinding surface and operable to receive a plunger comprising a complementary beveled grinding surface. Solid matrices placed within the diluent can be ground between the grinding surfaces to release molecules into the diluent for detection. The plunger may further comprise a groove containing a test strip operable to be deployed into the diluent after grinding for detection of the released molecules. In certain embodiments, the test strip may be a lateral flow immunoassay rapid antigen detection (LFA) test strip. The solid matrix may be a tick and the molecules may be antigens or pathogens related to tick-borne illnesses.

A method for a pre-symptomatic diagnosis of a viral illness includes obtaining a biological sample with a peripheral blood mononuclear cell from a subject. The method further includes stimulating the biological sample, where the stimulation of the biological sample includes adding to the biological sample a predetermined amount of antigen configured to trigger a T-cell IFN- response in the biological sample and a predetermined amount of reagent configured to capture the T-cell IFN- response. The method may even further include comparing the level of the T-cell IFN- response detected in the biological sample to a control sample level, the control sample level including a control sample T-cell IFN- response level detected in a control sample of the subject, where if the level of the T-cell IFN- response in the biological sample is at a predetermined amount greater than the control sample level, the subject is diagnosed with the viral illness.